These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 35615402)

  • 1. Deconstructing ADAURA. It is Not Yet Time to Forgo Platinum-based Adjuvant Chemotherapy in Resected Early Stage (IB-IIIA) EGFR-mutant NSCLC.
    Brazel D; Nagasaka M
    Lung Cancer (Auckl); 2022; 13():47-52. PubMed ID: 35615402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA
    Zhang SS; Ou SI
    Lung Cancer (Auckl); 2022; 13():23-31. PubMed ID: 35506019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osimertinib: A Review in Completely Resected, Early-Stage, EGFR Mutation-Positive NSCLC.
    Frampton JE
    Target Oncol; 2022 May; 17(3):369-376. PubMed ID: 35713772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC.
    Wu YL; John T; Grohe C; Majem M; Goldman JW; Kim SW; Kato T; Laktionov K; Vu HV; Wang Z; Lu S; Lee KY; Akewanlop C; Yu CJ; de Marinis F; Bonanno L; Domine M; Shepherd FA; Zeng L; Atasoy A; Herbst RS; Tsuboi M
    J Thorac Oncol; 2022 Mar; 17(3):423-433. PubMed ID: 34740861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant Osimertinib in Patients With Stage IB to IIIA EGFR Mutation-Positive NSCLC After Complete Tumor Resection: ADAURA China Subgroup Analysis.
    Wang J; Wu YL; Lu S; Wang Q; Li S; Zhong WZ; Wang Q; Li W; Wang B; Chen J; Cheng Y; Duan H; Li G; Shan L; Liu Y; Liu J; Huang X; Bolanos A; He J
    JTO Clin Res Rep; 2024 Feb; 5(2):100621. PubMed ID: 38371194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.
    Herbst RS; Wu YL; John T; Grohe C; Majem M; Wang J; Kato T; Goldman JW; Laktionov K; Kim SW; Yu CJ; Vu HV; Lu S; Lee KY; Mukhametshina G; Akewanlop C; de Marinis F; Bonanno L; Domine M; Shepherd FA; Urban D; Huang X; Bolanos A; Stachowiak M; Tsuboi M
    J Clin Oncol; 2023 Apr; 41(10):1830-1840. PubMed ID: 36720083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The value of disease-free survival (DFS) and osimertinib in adjuvant non-small-cell lung cancer (NSCLC): an international Delphi consensus report.
    Hardenberg MC; Patel B; Matthews C; Califano R; Garcia Campelo R; Grohe C; Hong MH; Liu G; Lu S; de Marinis F; Pérol M; Soo RA; Stiles BM; Tiseo M; Tsuboi M
    ESMO Open; 2022 Oct; 7(5):100572. PubMed ID: 36108559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer.
    Melosky B; Cheema P; Juergens RA; Leighl NB; Liu G; Wheatley-Price P; Sacher A; Snow S; Tsao MS; McLeod D; Chu Q
    Ther Adv Med Oncol; 2021; 13():17588359211056306. PubMed ID: 34804219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant Treatments for Surgically Resected Non-Small Cell Lung Cancer Harboring EGFR Mutations: A Review.
    Passaro A; Mok TSK; Attili I; Wu YL; Tsuboi M; de Marinis F; Peters S
    JAMA Oncol; 2023 Aug; 9(8):1124-1131. PubMed ID: 37166792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Clinicopathologic and Molecular Tumor Features With Recurrence in Resected Early-Stage Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer.
    Saw SPL; Zhou S; Chen J; Lai G; Ang MK; Chua K; Kanesvaran R; Ng QS; Jain A; Tan WL; Rajasekaran T; Lim DWT; Tan A; Fong KW; Takano A; Cheng XM; Lim KH; Koh T; Ong BH; Tan EH; Toh CK; Skanderup AJ; Tan SH; Tan DSW
    JAMA Netw Open; 2021 Nov; 4(11):e2131892. PubMed ID: 34739062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer.
    Ortega-Franco A; Rafee S
    Oncol Ther; 2022 Jun; 10(1):13-22. PubMed ID: 35294773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant therapies in stages I-III epidermal growth factor receptor-mutated lung cancer: current and future perspectives.
    Kris MG; Mitsudomi T; Peters S
    Transl Lung Cancer Res; 2023 Apr; 12(4):824-836. PubMed ID: 37197636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rational application of EGFR-TKI adjuvant therapy in patients with completely resected stage IB-IIIA EGFR-mutant NSCLC: a systematic review and meta-analysis of 11 randomized controlled trials.
    Zhang SL; Yi XF; Huang LT; Sun L; Ma JT; Han CB
    BMC Cancer; 2023 Aug; 23(1):719. PubMed ID: 37528390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overall Survival with Osimertinib in Resected
    Tsuboi M; Herbst RS; John T; Kato T; Majem M; Grohé C; Wang J; Goldman JW; Lu S; Su WC; de Marinis F; Shepherd FA; Lee KH; Le NT; Dechaphunkul A; Kowalski D; Poole L; Bolanos A; Rukazenkov Y; Wu YL;
    N Engl J Med; 2023 Jul; 389(2):137-147. PubMed ID: 37272535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR mutation prevalence, real-world treatment patterns, and outcomes among patients with resected, early-stage, non-small cell lung cancer in Canada.
    Sara Kuruvilla M; Liu G; Syed I; Gwadry-Sridhar F; Sheffield BS; Sachdeva R; Pencz A; Zhan L; Hueniken K; Patel D; Balaratnam K; Khan K; Grant B; Noy S; Singh K; Liu L; Rakibuz-Zaman M; Moldaver D; Kate Shanahan M; Cheema PK
    Lung Cancer; 2022 Nov; 173():58-66. PubMed ID: 36152478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial.
    Majem M; Goldman JW; John T; Grohe C; Laktionov K; Kim SW; Kato T; Vu HV; Lu S; Li S; Lee KY; Akewanlop C; Yu CJ; de Marinis F; Bonanno L; Domine M; Shepherd FA; Atagi S; Zeng L; Kulkarni D; Medic N; Tsuboi M; Herbst RS; Wu YL
    Clin Cancer Res; 2022 Jun; 28(11):2286-2296. PubMed ID: 35012927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial.
    John T; Grohé C; Goldman JW; Shepherd FA; de Marinis F; Kato T; Wang Q; Su WC; Choi JH; Sriuranpong V; Melotti B; Fidler MJ; Chen J; Albayaty M; Stachowiak M; Taggart S; Wu YL; Tsuboi M; Herbst RS; Majem M
    J Thorac Oncol; 2023 Sep; 18(9):1209-1221. PubMed ID: 37236398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of platinum-based adjuvant chemotherapy for epidermal growth factor receptor-mutant lung adenocarcinoma.
    Onodera K; Yokota I; Matsumura Y; Hayasaka K; Shiono S; Abe J; Notsuda H; Sakurada A; Suzuki H; Okada Y
    J Thorac Dis; 2023 Dec; 15(12):6534-6543. PubMed ID: 38249908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials.
    Zhao P; Zhen H; Zhao H; Zhao L; Cao B
    BMC Cancer; 2022 Mar; 22(1):328. PubMed ID: 35346117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer.
    Wu YL; Tsuboi M; John T; Grohe C; Majem M; Goldman JW; Laktionov K; Kim SW; Kato T; Vu HV; Lu S; Lee KY; Akewanlop C; Yu CJ; de Marinis F; Bonanno L; Domine M; Shepherd FA; Zeng L; Hodge R; Atasoy A; Rukazenkov Y; Herbst RS
    Future Oncol; 2021 Dec; 17(35):4827-4835. PubMed ID: 34723634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.